Alexandra V Kimchy, Harjit Singh, Esha Parikh, Jessica Rosenberg, Kavya Sanghavi, James H Lewis. The predictive value of liver tests for the presence of liver metastases.Hepatic oncology. 2023, 10 (3): HEP48
Abdalla Aly, Nicole Fulcher, Brian Seal, Trang Pham, Yunfei Wang, Scott Paulson, Aiwu R He. Clinical outcomes by Child-Pugh Class in patients with advanced hepatocellular carcinoma in a community oncology setting.Hepatic oncology. 2023, 10 (1): HEP47
Tasneem Lokhandwala, Abdalla Aly, Eileen Farrelly, Joanne P Willey, Lois E Lamerato, Marcus Healey, Anna D Coutinho, Brian S Seal. Management of hepatocellular carcinoma from diagnosis in routine clinical practice.Hepatic oncology. 2022, 9 (4): HEP45
Eduardo Crespo, Antonio Hermosín, Álvaro Villalba, Eduardo Daguer, José Flores, Javier Periañez, Mario Martínez-Galdámez, Ernesto Santos. Uncooled TATO microwave system for liver ablation.Hepatic oncology. 2022, 9 (4): HEP46
Gokula Kumar Appalanaido, Muhamad Zabidi Ahmad, Syadwa Abdul Shukor, Alex Khoo Cheen Hoe, Manisekar K Subramaniam, Ang Soo Fan, Mohd Zahri Abdul Aziz. Pathological complete response with immunotherapy and brachytherapy to 15 metastatic liver lesions in a single patient.Hepatic oncology. 2022, 9 (3): HEP44
Ellery Altshuler, Mahmoud Aryan, Govind Kallumkal, Hanzhi Gao, Jake Wilson, Ahmed Ouni, Edward De Leo, Wissam Hanayneh, Kelsey Pan. Impact of β-blockers on survival outcomes in patients with unresectable hepatocellular carcinoma.Hepatic oncology. 2022, 9 (2): HEP43
Mary Wong, Jong T Kim, Brian Cox, Brent K Larson, Stacey Kim, Kevin M Waters, Eric Vail, Maha Guindi. Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma.Hepatic oncology. 2021, 8 (4): HEP39
Abdalla Aly, Melissa Lingohr-Smith, Jay Lin, Brian Seal. Locoregional therapy patterns and healthcare economic burden of patients with hepatocellular carcinoma in the USA.Hepatic oncology. 2021, 8 (3): HEP37
Diana Julie Leeming, Signe Holm Nielsen, Roslyn Vongsuvanh, Pruthviraj Uchila, Mette Juul Nielsen, Alexander L Reese-Petersen, David van der Poorten, Mohammed Eslam, Detlef Schuppan, Morten Asser Karsdal, Jacob George. Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma.Hepatic oncology. 2020, 8 (2): HEP32